Categories:
Whitepaper: Medicinal Cannabis Products – Regulatory differences between Brazilian and Mexican Legislations
We have published our new Whitepaper that describes the main differences between Mexican and Brazili
Ler mais
ANVISA – Update of the Guideline 20/2019 on topical and transdermal products
ANVISA published the second version of Guideline 20/2019, which provides guidance on quality require
Ler mais
EMA – Review of the Question and Answer Documents for Centralized Procedure
On February 2021, the European Medicines Agency (EMA) published on its website an updated version of
Ler mais
Whitepaper: Diffferences between CTD Brazil and UE: a look at CMC requirements
Our daily lives at Vita are full of discussions about technical and regulatory differences in the re
Ler mais
Whitepaper: Diffferences between CTD Brazil and UE: a look at CMC requirements
Our daily lives at Vita are full of discussions about technical and regulatory differences in the re
Ler mais
ANVISA – Public Consultation for Revision of RDC 47/2009, which establishes the rules for drug package leaflet
On December 2020, ANVISA published the Public Consultation for Revision of DRC Nº 47 of September 8
Ler mais
EMA publishes Questions and Answers document on Brexit
On January 1, 2021, the United Kingdom (UK) will be considered a “third country” with i
Ler mais
ANVISA – Resolution RDC 753/2022 – Review to RDC 200/2017 – Marketing Authorization of New, Innovative, Generic and Similar Medicinal Products – updated on October 10th, 2022
On October 7, at Public Ordinary Meeting ANVISA 19/2020, it was approved the draft for Public Co
Ler mais
ANVISA – Questions & Answers on RDC 359/2020, which instituted DIFA and CADIFA for API used in the manufacture of Drug Products
On September 28th, ANVISA published the document Questions & Answers on RDC 359/2020, whi
Ler mais
ANVISA – Service Guidance on flows for analysis of drug product application
On September 23, ANVISA published Service Orientation (OS) 90/2020, from the General Management of M
Ler mais
ANVISA – New Legislation in Pharmacovigilance
On July 29th, it was published on Brazilian Official Gazette (DOU) the RDC Nº 406/2020, regarding t
Ler mais
ANVISA – New Public Consultations for Simplified Notification of Low-Risk Medicines
On June 3, two Public Consultations regarding the Simplified Notification of Low Risk Medicines were
Ler mais